← Back to all trials
Not Yet Recruiting
NCT07846176
Aficamten and Patient-Reported Outcomes in Real-World nHCM
Conditions: Hypertrophic Cardiomyopathy (HCM)
Sex: All
Ages: 18 Years – 85 Years
Healthy volunteers: No
Enrollment: 100
Sponsor: Second Affiliated Hospital, Zhejiang University, School of Medicine
Summary
This multicenter, prospective, observational, real-world clinical study aims to evaluate the efficacy and safety of Aficamten in patients with symptomatic non-obstructive hypertrophic cardiomyopathy (nHCM) by prospectively observing changes in symptoms, biomarkers, imaging findings, and adverse reactions, etc. It will also record the dosing regimens at which individual patients achieve steady state, and explore the treatment patterns of Aficamten in Chinese patients with symptomatic nHCM.
Eligibility Criteria
Inclusion Criteria:
* Age 18-85 years.
* Confirmed diagnosis of HCM:
1. Left ventricular wall thickness ≥15 mm at any site on echocardiography or cardiac magnetic resonance.
2. Left ventricular wall thickness ≥13 mm in individuals testing positive for a pathogenic variant or in genetically affected family members.
3. Ventricular wall thickening caused by other cardiovascular diseases or systemic or metabolic disorders has been excluded.
* Symptomatic nHCM patients meeting all of the following conditions:
1. Left ventricular outflow tract gradient (LVOTG) \
Source: ClinicalTrials.gov (NCT07846176). StuddyBuddy aggregates publicly available trial information.
